Northern Trust’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$75.5K Sell
5,731
-11,881
-67% -$265K ﹤0.01% 4188
2026
Q1
$463K Sell
17,612
-95
-0.5% -$11.9K ﹤0.01% 3643
2025
Q4
$4.39M Sell
17,707
-986
-5% -$225K ﹤0.01% 2548
2025
Q3
$3.93M Sell
18,693
-309
-2% -$54.5K ﹤0.01% 2641
2025
Q2
$1.87M Buy
19,002
+13,876
+271% +$1.21M ﹤0.01% 3028
2025
Q1
$451K Sell
5,126
-16
-0.3% -$1.48K ﹤0.01% 3617
2024
Q4
$372K Buy
5,142
+8
+0.2% +$548 ﹤0.01% 3758
2024
Q3
$405K Sell
5,134
-379
-7% -$29.2K ﹤0.01% 3640
2024
Q2
$397K Buy
5,513
+681
+14% +$40.8K ﹤0.01% 3593
2024
Q1
$456K Sell
4,832
-703
-13% -$61.9K ﹤0.01% 3589
2023
Q4
$404K Buy
5,535
+75
+1% +$4.43K ﹤0.01% 3612
2023
Q3
$364K Buy
5,460
+3,005
+122% +$277K ﹤0.01% 3602
2023
Q2
$236K Sell
2,455
-5,155
-68% -$514K ﹤0.01% 3761
2023
Q1
$767K Sell
7,610
-636
-8% -$97.4K ﹤0.01% 3308
2022
Q4
$1.43M Sell
8,246
-179
-2% -$118K ﹤0.01% 3147
2022
Q3
$8.07M Buy
8,425
+587
+7% +$583K ﹤0.01% 2143
2022
Q2
$5.25M Buy
7,838
+436
+6% +$270K ﹤0.01% 2479
2022
Q1
$5.14M Sell
7,402
-74
-1% -$57.1K ﹤0.01% 2572
2021
Q4
$6.76M Sell
7,476
-29
-0.4% -$27.6K ﹤0.01% 2514
2021
Q3
$7.55M Sell
7,505
-98
-1% -$72.2K ﹤0.01% 2472
2021
Q2
$4.94M Buy
7,603
+64
+0.8% +$44.4K ﹤0.01% 2846
2021
Q1
$5.58M Sell
7,539
-648
-8% -$523K ﹤0.01% 2679
2020
Q4
$6.33M Sell
8,187
-282
-3% -$222K ﹤0.01% 2538
2020
Q3
$8.41M Buy
8,469
+420
+5% +$445K ﹤0.01% 2207
2020
Q2
$8.37M Buy
8,049
+1,559
+24% +$1.57M ﹤0.01% 2210
2020
Q1
$5.27M Sell
6,490
-6
-0.1% -$6.27K ﹤0.01% 2274
2019
Q4
$8.12M Buy
6,496
+138
+2% +$222K ﹤0.01% 2314
2019
Q3
$8.54M Buy
6,358
+4,110
+183% +$6.54M ﹤0.01% 2245
2019
Q2
$3.99M Buy
2,248
+205
+10% +$314K ﹤0.01% 2675
2019
Q1
$3.54M Buy
+2,043
New +$3.41M ﹤0.01% 2753

Other funds holding GOSS

Northern Trust's GOSS Position: Q2 2026 in Review

Northern Trust reduced its Gossamer Bio (GOSS) stake by 67% in Q2 2026, selling an estimated $265K and leaving 5,731 shares worth $75.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4188.

Northern Trust first reported a position in GOSS in Q1 2019 and has held it in 30 quarters since. The position peaked at $8.54M in Q3 2019. 166 funds tracked by Wall St. Rank hold GOSS as of Q2 2026.

  • Northern Trust held 5,731 shares of Gossamer Bio worth $75.5K as of Q2 2026.
  • Northern Trust sold 11,881 Gossamer Bio shares in Q2 2026, an estimated $265K.
  • Gossamer Bio made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4188 holding.
  • Northern Trust first reported a position in Gossamer Bio in Q1 2019 and has held it in 30 quarters since.
  • Northern Trust's Gossamer Bio position peaked at $8.54M in Q3 2019.
  • 166 funds tracked by Wall St. Rank held Gossamer Bio as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.